Inhibikase Therapeutics, Inc. (IKT) Return on Tangible Equity

Inhibikase Therapeutics, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

• Inhibikase Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -39.55%, a change of 12.30% year-over-year.
• Inhibikase Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -30.40%, a change of 12.23% year-over-year.
• Inhibikase Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was -27.91%, a change of 1.10% year-over-year.
• Inhibikase Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -65.37%, a 101.77% decline year-over-year.
• Inhibikase Therapeutics, Inc. return tang equity for fiscal 2025 was -27.91%, a change of 1.10% from fiscal 2024.
• Inhibikase Therapeutics, Inc. return tang equity for fiscal 2024 was -29.01%, a change of 144.33% from fiscal 2023.
• Inhibikase Therapeutics, Inc. return tang equity for fiscal 2023 was -173.34%, a change of -87.51% from fiscal 2022.
• Inhibikase Therapeutics, Inc. return tang equity for fiscal 2022 was -85.83%, a change of -47.34% from fiscal 2021.